THE WERNER GROUP

View full entity profile (contributions, contracts, SEC) →

Lobbying Income

$897K

Filings

Unique Clients

Active Period

2005–2009

Lobbying Income by Year

Registrant-reported income from clients on LDA filings

Year	Lobbying Income	Filings	Clients
2009	$45,000	2	2
2008	$280,000	9	2
2007	$297,000	9	4
2006	$185,000	5	3
2005	$90,000	5	2

Top Clients

Largest clients by registrant-reported income

Client	Reported Income	Filings	Period
BIOTECHNOLOGY INDUSTRY ORGANIZATION	$490,000	11	2005–2009
UCARE MINNESOTA	$147,000	6	2005–2007
SHIRE PHARMACEUTICALS	$140,000	6	2008–2009
Shire Human Genetic Therapies AB	$80,000	3	2007
COMMUNITY HEALTH CHARITIES	$40,000	4	2006–2007

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	24
SENATE	22

Top Issues Lobbied

Most frequently reported lobbying issues

Issue Code	Description	Reports
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	20
Medicare/Medicaid	Medicare/Medicaid	7
Health Issues	Health Issues	5
Science/Technology	Science/Technology	1

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 1427111th Congress

Promoting Innovation and Access to Life-Saving Medicine Act

2009 · first_quarter · Client: SHIRE PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

HR 1548 Pathway for Biosimilars Act -- focus on orphan drug issues HR 1427 Promoting Innovation and Access to Life Saving Medicine Act -- focus on orphan drug issues

Client expense: — · Firm income: $20,000

Matched citations: HR 1427

H.R. 1548111th Congress

Pathway for Biosimilars Act

2009 · first_quarter · Client: SHIRE PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

HR 1548 Pathway for Biosimilars Act -- focus on orphan drug issues HR 1427 Promoting Innovation and Access to Life Saving Medicine Act -- focus on orphan drug issues

Client expense: — · Firm income: $20,000

Matched citations: HR 1548

H.R. 872111th Congress

Stem Cell Research Improvement Act of 2009

2009 · first_quarter · Client: BIOTECHNOLOGY INDUSTRY ORGANIZATION

Open original LDA filing ↗

Cited source text and reported amounts

HR 873, S 487 The Stem Cell Research Enhacement Act of 2009 HR 872, The Stem Cell Research Improvement Act of 2009

Client expense: — · Firm income: $25,000

Matched citations: HR 872

H.R. 873111th Congress

Stem Cell Research Enhancement Act of 2009

2009 · first_quarter · Client: BIOTECHNOLOGY INDUSTRY ORGANIZATION

Open original LDA filing ↗

Cited source text and reported amounts

HR 873, S 487 The Stem Cell Research Enhacement Act of 2009 HR 872, The Stem Cell Research Improvement Act of 2009

Client expense: — · Firm income: $25,000

Matched citations: HR 873

Show 21 more cited filings

S. 487111th Congress

Stem Cell Research Enhancement Act of 2009

2009 · first_quarter · Client: BIOTECHNOLOGY INDUSTRY ORGANIZATION

Open original LDA filing ↗

Cited source text and reported amounts

HR 873, S 487 The Stem Cell Research Enhacement Act of 2009 HR 872, The Stem Cell Research Improvement Act of 2009

Client expense: — · Firm income: $25,000

Matched citations: S 487

H.R. 5629110th Congress

Pathway for Biosimilars Act

2008 · fourth_quarter · Client: SHIRE PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

HR 5629 Pathway for Biosimilars Act

Client expense: — · Firm income: $30,000

Matched citations: HR 5629

H.R. 7141110th Congress

Stem Cell Research Enhancement Act of 2008

2008 · fourth_quarter · Client: BIOTECHNOLOGY INDUSTRY ORGANIZATION

Open original LDA filing ↗

Cited source text and reported amounts

The Stem Cell Research Enhancement Act, HR 7141

Client expense: — · Firm income: $40,000

Matched citations: HR 7141

H.R. 5629110th Congress

Pathway for Biosimilars Act

2008 · third_quarter · Client: SHIRE PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

HR 5629 Pathway for Biosimilars Act

Client expense: — · Firm income: $30,000

Matched citations: HR 5629

H.R. 7141110th Congress

Stem Cell Research Enhancement Act of 2008

2008 · third_quarter · Client: BIOTECHNOLOGY INDUSTRY ORGANIZATION

Open original LDA filing ↗

Cited source text and reported amounts

Stem Cell Research Enhancement Act of 2008 HR 7141

Client expense: — · Firm income: $40,000

Matched citations: HR 7141

H.R. 1634110th Congress

Newborn Screening Saves Lives Act of 2007

2008 · second_quarter · Client: SHIRE PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

HR 1634, S. 634, S. 1858 Newborn Screening Saves Lives Act of 2007 HR 5629 Pathway for Biosimilars Act

Client expense: — · Firm income: $30,000

Matched citations: HR 1634

H.R. 5629110th Congress

Pathway for Biosimilars Act

2008 · second_quarter · Client: SHIRE PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

HR 1634, S. 634, S. 1858 Newborn Screening Saves Lives Act of 2007 HR 5629 Pathway for Biosimilars Act

Client expense: — · Firm income: $30,000

Matched citations: HR 5629

S. 1858110th Congress

Newborn Screening Saves Lives Act of 2007

2008 · second_quarter · Client: SHIRE PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

HR 1634, S. 634, S. 1858 Newborn Screening Saves Lives Act of 2007 HR 5629 Pathway for Biosimilars Act

Client expense: — · Firm income: $30,000

Matched citations: S. 1858

S. 634110th Congress

Newborn Screening Saves Lives Act of 2007

2008 · second_quarter · Client: SHIRE PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

HR 1634, S. 634, S. 1858 Newborn Screening Saves Lives Act of 2007 HR 5629 Pathway for Biosimilars Act

Client expense: — · Firm income: $30,000

Matched citations: S. 634

H.R. 3110th Congress

Stem Cell Research Enhancement Act of 2007

2008 · second_quarter · Client: BIOTECHNOLOGY INDUSTRY ORGANIZATION

Open original LDA filing ↗

Cited source text and reported amounts

Stem Cell Research Enhancement Act of 2007 (S.5 and HR 3)

Client expense: — · Firm income: $40,000

Matched citations: HR 3

S. 5110th Congress

Stem Cell Research Enhancement Act of 2007

2008 · second_quarter · Client: BIOTECHNOLOGY INDUSTRY ORGANIZATION

Open original LDA filing ↗

Cited source text and reported amounts

Stem Cell Research Enhancement Act of 2007 (S.5 and HR 3)

Client expense: — · Firm income: $40,000

Matched citations: S.5

H.R. 3110th Congress

Stem Cell Research Enhancement Act of 2007

2008 · first_quarter · Client: BIOTECHNOLOGY INDUSTRY ORGANIZATION

Open original LDA filing ↗

Cited source text and reported amounts

Stem Cell Research Enhancement Act of 2007 (S.5 and HR 3)

Client expense: — · Firm income: $40,000

Matched citations: HR 3

S. 5110th Congress

Stem Cell Research Enhancement Act of 2007

2008 · first_quarter · Client: BIOTECHNOLOGY INDUSTRY ORGANIZATION

Open original LDA filing ↗

Cited source text and reported amounts

Stem Cell Research Enhancement Act of 2007 (S.5 and HR 3)

Client expense: — · Firm income: $40,000

Matched citations: S.5

H.R. 1634110th Congress

Newborn Screening Saves Lives Act of 2007

2008 · first_quarter · Client: SHIRE PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

HR 1634, S. 634, S. 1858 Newborn Screening Saves Lives Act of 2007 HR 5629 Pathway for Biosimilars Act

Client expense: — · Firm income: $30,000

Matched citations: HR 1634

H.R. 5629110th Congress

Pathway for Biosimilars Act

2008 · first_quarter · Client: SHIRE PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

HR 1634, S. 634, S. 1858 Newborn Screening Saves Lives Act of 2007 HR 5629 Pathway for Biosimilars Act

Client expense: — · Firm income: $30,000

Matched citations: HR 5629

S. 1858110th Congress

Newborn Screening Saves Lives Act of 2007

2008 · first_quarter · Client: SHIRE PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

HR 1634, S. 634, S. 1858 Newborn Screening Saves Lives Act of 2007 HR 5629 Pathway for Biosimilars Act

Client expense: — · Firm income: $30,000

Matched citations: S. 1858

S. 634110th Congress

Newborn Screening Saves Lives Act of 2007

2008 · first_quarter · Client: SHIRE PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

HR 1634, S. 634, S. 1858 Newborn Screening Saves Lives Act of 2007 HR 5629 Pathway for Biosimilars Act

Client expense: — · Firm income: $30,000

Matched citations: S. 634

H.R. 3825110th Congress

Newborn Screening Saves Lives Act of 2008

2008 · first_quarter · Client: SHIRE PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

HR 5629 The Pathway for Biosimilars Act HR 3825 The Newborn Screening Saves Lives Act Reimbursement for home infusion services under Medicare

Client expense: — · Firm income: —

Matched citations: HR 3825

H.R. 3825110th Congress

Newborn Screening Saves Lives Act of 2008

2008 · first_quarter · Client: SHIRE PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

HR 5629 The Pathway for Biosimilars Act HR 3825 The Newborn Screening Saves Lives Act Reimbursement for home infusion services under Medicare

Client expense: — · Firm income: —

Matched citations: HR 3825

H.R. 5629110th Congress

Pathway for Biosimilars Act

2008 · first_quarter · Client: SHIRE PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

HR 5629 The Pathway for Biosimilars Act HR 3825 The Newborn Screening Saves Lives Act Reimbursement for home infusion services under Medicare

Client expense: — · Firm income: —

Matched citations: HR 5629

H.R. 5629110th Congress

Pathway for Biosimilars Act

2008 · first_quarter · Client: SHIRE PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

HR 5629 The Pathway for Biosimilars Act HR 3825 The Newborn Screening Saves Lives Act Reimbursement for home infusion services under Medicare

Client expense: — · Firm income: —

Matched citations: HR 5629

Source: Senate LDA

THE WERNER GROUP — Lobbying Disclosure | Poliscope